ArticleIrish journal of medical science2026
Efficacy and safety of micropulse transscleral cyclophotocoagulation in glaucoma: a two-year retrospective audit cohort.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of micropulse transscleral cyclophotocoagulation in glaucoma: a two-year retrospective audit cohort.Irish journal of medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo retrospectively evaluate the efficacy and safety of Micropulse Transscleral Cyclophotocoagulation (MP-TSCPC) in reducing intraocular pressure (IOP) and the number of glaucoma medications in patients with different types of glaucoma over a two-year period.
methodsThis retrospective audit included 52 eyes from 32 patients treated with MP-TSCPC at Mountainhall Treatment Centre, Dumfries, UK, between August 2021 and September 2023. Standard treatment parameters included 2500 mW power applied for 10 s per quadrant across 9 cycles. Primary outcomes were changes in IOP and the number of glaucoma medications. Secondary outcomes included postoperative complications and changes in the mean deviation of the visual field (MD).
resultsThe mean preoperative IOP was 21.4 mmHg, which significantly decreased postoperatively to 11.9 mmHg at 4 weeks, 12.75 mmHg at 3 months, 13.4 mmHg at 1 year, and 14.03 mmHg at 2 years. The median IOP reduction at 1 year was 5.0 mmHg with statistical significance (p < 0.0001). The average number of topical medications declined from 2.21 eye drops to 1.58 eye drops. No statistically significant change was observed in visual field MD (p = 0.4838), though disease progression appeared to stabilize (mean MD: -7.1 dB). Complications were infrequent and included mild anterior uveitis (n = 12), cystoid macular edema, recurrence of herpetic keratitis and severe ocular inflammation (n = 1).
conclusionMP-TSCPC is a safe and effective procedure for medium-term IOP control, particularly in patients with primary open-angle glaucoma. It significantly reduces IOP and medication dependency, with a low complication profile. However, outcomes are more variable in secondary glaucoma, especially uveitic cases. These findings support the growing role of MP-TSCPC as a minimally invasive treatment option for glaucoma.
Indexed as
Identifiers
41498999What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.